Condition
C3 Glomerulopathy clinical trials and research
As of November 12, 2026, Find a Trial lists 5 C3 Glomerulopathy clinical trials that are recruiting, at sites in 19 countries (most in United Kingdom (2), United States (2), Argentina (1)). By phase: Phase 3 (1), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 19Countries
Newest C3 Glomerulopathy clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Iptacopan use in Korean patients with PNH or C3G | — | Jeollanam and 2 other locations | Recruiting | Feb 18, 2026 |
| Home-reported outcomes for people with C3 Glomerulopathy | — | East Hanover, New Jersey | Recruiting | Jun 19, 2025 |
| National Registry for Rare Kidney Diseases | — | Bristol, South West | Recruiting | Oct 4, 2023 |
| Comparing Aliskiren and Enalapril for C3 Glomerulopathy Treatment | Phase 2 | Gothenburg and 3 other locations | Recruiting | Dec 3, 2019 |
| Long-term treatment with iptacopan for C3 glomerulopathy and IC-MPGN | Phase 3 | Aurora, Colorado and 52 other locations | Recruiting | May 20, 2019 |
All recruiting trials (5)
-
Iptacopan use in Korean patients with PNH or C3G
This post-marketing surveillance study tests how well iptacopan works and how safe it is for Korean adults with PNH or C3G in real-world care.
-
Home-reported outcomes for people with C3 Glomerulopathy
This project will collect monthly home-reported symptoms, treatment use, and quality-of-life information from adults with C3 glomerulopathy and their caregivers to see how these change over time.
-
National Registry for Rare Kidney Diseases
This study is collecting health information from people with rare kidney diseases to help improve treatments and create better care guidelines.
-
Comparing Aliskiren and Enalapril for C3 Glomerulopathy Treatment
This study is testing whether a new kidney treatment called aliskiren works better than the standard treatment enalapril for people with C3 glomerulopathy.
-
Long-term treatment with iptacopan for C3 glomerulopathy and IC-MPGN
This study is testing if the medication iptacopan can safely help people with C3 glomerulopathy or immune-complex-membranoproliferative glomerulonephritis over a longer period of time.
Related topics
Quick answers
How many C3 Glomerulopathy clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 19 countries. The most sites are in United Kingdom (2 trials), United States (2 trials), Argentina (1 trial), Brazil (1 trial), Canada (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 1, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.